U.S., Oct. 29 -- ClinicalTrials.gov registry received information related to the study (NCT07901595) titled 'Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PAL-119 in Healthy Volunteers and Adult Participants With Type 1 or Type 2 Diabetes' on Oct. 22.
Brief Summary: This is a Phase 1/2 randomized study of oral doses of PAL-119 in healthy volunteers and participants with diabetes.
Study Start Date: Nov. 01
Study Type: INTERVENTIONAL
Condition:
Healthy Volunteers and Diabetes Participants
Intervention:
DRUG: PAL-119
Small synthetic molecule
DRUG: Placebo
Placebo
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Paulex Bio Inc.
Published by HT Digital Content Services with permission from Health Daily Digest....